Development features and clinical presentation
This pathology is one of the most common types of leukemia. The clinical picture remains latent for a long time, and the disease often manifests asymptomatically, being discovered as an incidental finding during a routine blood test. As the process slowly progresses, the patient begins to notice increasing weakness and fatigue.
Specific symptoms are due to lymphocytic infiltration of tissues:
- Lymphadenopathy. The formation of massive conglomerate lymph nodes is characteristic (especially in the mediastinum and abdominal cavity). Large foci can lead to mechanical compression of neighboring organs, such as the trachea.
- Organomegaly. Hepatomegaly and splenomegaly develop.
- Anemic syndrome. There is a pronounced tendency toward anemia, including due to mechanisms of autoimmune hemolysis.
Unlike acute leukemias, classic hemorrhagic syndrome is usually absent at the onset of the disease.
Laboratory diagnostics and blood picture
Laboratory tests play a key role in making the diagnosis. The peripheral blood picture reveals a significant increase in the total leukocyte count.
- Lymphocytosis. Up to 95% of all circulating cells are represented by lymphocytes (predominantly small ones). The number of young forms (lymphoblasts and prolymphocytes), conversely, is reduced.
- Gumprecht shadows (smudge cells). This is a pathognomonic sign of the disease. It represents degraded lymphocyte nuclei that are easily damaged during the preparation of a blood smear.
Bone marrow examination of the punctate reveals that the lymphocyte count exceeds 30%. Trephine biopsy material reveals diffuse lymphatic hyperplasia and erythroblast dysplasia. The latter is a sign of relative folic acid deficiency, which is excessively consumed during active proliferation.
The biochemical profile also changes: immunoglobulin levels can be either decreased or increased. Due to the massive destruction of lymphocyte nuclei, hyperuricemia occurs in the blood.
Complications and treatment approaches
Despite the fact that B lymphocytes produce immunoglobulins (most often monoclonal), immunity turns out to be functionally incompetent. This leads to severe infectious complications. Patients are prone to frequent viral infections (especially herpetic ones) affecting the mucous membranes of the gastrointestinal tract and bronchi. Autoimmune reactions provoking secondary hemorrhagic syndrome and neurological disorders (polyneuritis, cranial nerve involvement) are also possible.
Therapeutic tactics are conservative: treatment is not started immediately after diagnosis. Indications for prescribing cytotoxic drugs are signs of progression:
- Impairment of the patient's general condition.
- Involvement and significant enlargement of lymph nodes and the spleen.
As part of chemotherapy, it is advisable to use alkylating agents (chlorambucil, cyclophosphamide) and purine analogues (fludarabine). In the presence of clinically significant leukemic infiltrates (for example, with compression of spinal cord structures), radiation therapy is indicated.
Briefly: answers to topical questions
What are all the causes of anemic syndrome in chronic lymphocytic leukemia?
Causes/factors of anemic syndrome in chronic lymphocytic leukemia explicitly stated in sources:
- Autoimmune hemolysis — indicated as a possible mechanism of anemic syndrome in CLL.
- Relative folic acid deficiency — associated with increased consumption of folic acid for proliferation; erythroblast dysplasia is described in trephine biopsy as a sign of such deficiency.
- Drug toxicity of alemtuzumab — hematological disorders, including anemia, are possible during alemtuzumab therapy for CLL.
Which targeted drugs (monoclonal antibodies, kinase inhibitors) are used in modern treatment regimens?
The sources explicitly mention the following targeted drugs and drug groups for the treatment of chronic lymphocytic leukemia:
- Alemtuzumab — a human monoclonal antibody drug; target — the CD52 receptor; used as monotherapy in chronic lymphocytic leukemia.
- Rituximab — can be used in combination with immunochemotherapy.
- Obinutuzumab — can be used in combination with immunochemotherapy.
- Bruton's tyrosine kinase (BTK) inhibitors — mentioned as targeted molecular drugs.
- BCL-2 inhibitors — mentioned as targeted drugs.
The "Three B's" rule for blood in CLL: Asymptomatically beginning, Big lymph nodes, Gumprecht shadows (smudge cells).
Class and exam questions
Why do infections frequently occur in chronic lymphocytic leukemia?
Although neoplastic B lymphocytes produce immunoglobulins, they are functionally incompetent. This leads to immune system disorders and frequent viral infections, especially herpetic ones.
When should chemotherapy be initiated after diagnosis?
Treatment is not started immediately. Cytotoxic drugs are indicated only upon signs of progression: deterioration of the patient's general condition or marked enlargement of lymph nodes and the spleen.
Is hemorrhagic syndrome encountered in this pathology?
In typical cases, it is absent, which is an important distinction from acute leukemias. However, it may appear later as a consequence of secondary autoimmune reactions.
What else to study on this topic
- Mechanisms of autoimmune hemolysis in lymphoproliferative disorders
- Features of diffuse lymphatic hyperplasia in trephine biopsy specimens
- Effect of folic acid deficiency on erythropoiesis in leukemias
- Mechanism of action of purine analogues in CLL chemotherapy
- Indications for radiation therapy in spinal cord compression by leukemic infiltrates
Master the entire topic in the "Propaedeutics" course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Chronic lymphocytic leukemia" and 3,152 other subject pages
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 113 video lessons on the subject
Other topics in the "Blood System" section
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.